A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

Lesley Taylor, Julie Crockett, Bola Tayo, Gilmour Morrison, Lesley Taylor, Julie Crockett, Bola Tayo, Gilmour Morrison

Abstract

The pharmacokinetics and safety of a single oral dose of 200-mg plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD) in oral solution (Epidiolex in the United States; 100 mg/mL) were assessed in subjects with mild to severe hepatic impairment (n = 8 each for mild and moderate, n = 6 for severe) relative to matched subjects with normal hepatic function (n = 8). Blood samples were collected until 48 hours after dosing and evaluated by liquid chromatography and tandem mass spectrometry. Pharmacokinetic parameters (primarily maximum measured plasma concentration, area under the plasma concentration-time curve from time zero to time t, area under the concentration-time curve from time zero to infinity, time to maximum plasma concentration, and terminal half-life) of CBD and its major metabolites were derived using non-compartmental analysis. CBD was rapidly absorbed in all groups independent of hepatic function (median time to maximum plasma concentration, 2-2.8 hours). Exposure (area under the concentration-time curve from time zero to infinity) to total CBD slightly increased in subjects with mild hepatic impairment (geometric mean ratio [GMR], 1.48; 90% confidence interval [CI], 0.90-2.41). However, there were clinically relevant increases in subjects with moderate (GMR, 2.45; 90%CI, 1.50-4.01) and severe (GMR, 5.15; 90%CI, 2.94-9.00) hepatic impairment, relative to subjects with normal hepatic function. Exposure to the CBD metabolites (6-hydroxy-CBD and 7-hydroxy-CBD) also increased in subjects with moderate and severe hepatic impairment, but to a lesser extent than the parent drug. The 7-carboxy-CBD metabolite exposure was lower in subjects with severe hepatic impairment when compared with subjects with normal liver function. These findings indicate that dose modification is necessary in patients with moderate and severe hepatic impairment, and a lower starting dose and slower titration are necessary based on benefit-risk. CBD was well tolerated, and there were no serious adverse events reported during the trial.

Keywords: cannabidiol; cannabinoid; hepatic impairment; liver function; pharmacokinetic.

© 2019 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology.

Figures

Figure 1
Figure 1
Arithmetic mean (± standard deviation) plasma concentration–time profiles for cannabidiol (CBD), 6‐OH‐CBD, 7‐OH‐CBD, and 7‐COOH‐CBD after a single oral 200 mg CBD dose, by hepatic function group (semilogarithmic); pharmacokinetic analysis set.

References

    1. Devinsky O, Cross JH, Laux L, et al. Cannabidiol in Dravet Syndrome Study Group: trial of cannabidiol for drug‐resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011‐2020.
    1. Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose‐ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204‐e1211.
    1. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox‐Gastaut syndrome. N Engl J Med. 2018;378(20):1888‐1897.
    1. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox‐Gastaut syndrome (GWPCARE4): a randomised, double‐blind, placebo‐controlled phase 3 trial. Lancet 2018;391(10125):1085‐1096.
    1. EPIDIOLEX USPI . Highlights of prescribing information: EPIDIOLEX® (cannabidiol) oral solution. . Accessed September 5, 2018.
    1. Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699‐730.
    1. Henstridge CM, Balenga NA, Kargl J, et al. Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol‐sensitive receptor GPR55. Mol Endocrinol. 2011;25(11):1835‐1848.
    1. Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid‐ and lysophosphatidylinositol‐sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A. 2013;110(13):5193‐5198.
    1. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9)‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737‐753.
    1. Wall ME, Brine DR, Perez‐Reyes M. Metabolism of cannabinoids in man In: Braude MC, Szara S, eds. The Pharmacology of Marihuana. New York, NY: Raven Press; 1976:93‐113.
    1. Watanabe K, Fujinami M, Yamaori S, Yamamoto I. Possible involvement of Cyp3a enzymes in the metabolism of tetrahydrocannabinols by mouse brain microsomes. Forensic Toxicol. 2011;29:56‐60.
    1. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770‐1804.
    1. Ujvary I, Hanus L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 2016;1(1):90‐101.
    1. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89(5‐6):165‐170.
    1. Mazur A, Lichti CF, Prather PL et al. Characterization of human hepatic and extrahepatic UDP‐glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37(7):1496‐1504.
    1. Whalley B, Stott C, Gray R, Jones NA. Human metabolite of cannabidiol, 7‐hydroxy cannabidiol, but not 7‐carboxy cannabidiol, is anticonvulsant in the maximal electroshock seizure threshold (mEST) test in mouse. Abstract 1.435 American Epilepsy Society Meeting; 2017.
    1. Food and Drug Administration. Guidance for Industry : Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling; 2003.
    1. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. CPMP/EWP/2339/02, EMEA; 2005.
    1. World Medical Association Declaration of Helsinki . Ethical principles for medical research involving human subjects Edinburgh, Scotland; October 2000, including the footnote of October 2002.
    1. ICH Harmonised Tripartite Guideline : Guideline for good clinical practice E6(R1); June 1996.
    1. Tarantino G, Di Minno MN, Capone D. Drug‐induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009;15(23):2817‐2833.
    1. Elmes MW, Kaczocha M, Berger WT et al. Fatty acid‐binding proteins (FABPs) are intracellular carriers for Δ9‐tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem. 2015;290(14):8711‐8721.
    1. Stott CG, White L, Wright S, Wilbraham D, Guy GW. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013;69(4):825‐834.
    1. Wilsey BL, Deutsch R, Samara E, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res. 2016;9:587‐598.
    1. Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double‐blind, placebo‐controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053‐1067.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere